Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs Brentuximab vedotin (Primary) ; Dacarbazine; Doxorubicin; Granulocyte colony-stimulating factors; Nivolumab; Vinblastine
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Seattle Genetics
- 06 Nov 2019 Trial design released at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 23 Sep 2019 Phase changed from phase 4 to phase 2, one arm has been added, drug nivolumab has been added, hence the protocol was amended.
- 23 Sep 2019 Planned number of patients changed from 180 to 90.